Neuropace Stock Revenue
| NPCE Stock | USD 10.60 0.35 3.41% |
Neuropace fundamentals help investors to digest information that contributes to Neuropace's financial success or failures. It also enables traders to predict the movement of Neuropace Stock. The fundamental analysis module provides a way to measure Neuropace's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neuropace stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 65.4 M | 51.5 M |
Neuropace | Revenue |
Neuropace Company Revenue Analysis
Neuropace's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Neuropace Revenue | 65.42 M |
Most of Neuropace's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neuropace is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Neuropace
Projected quarterly revenue analysis of Neuropace provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Neuropace match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Neuropace's stock price.
Neuropace Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Neuropace is extremely important. It helps to project a fair market value of Neuropace Stock properly, considering its historical fundamentals such as Revenue. Since Neuropace's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Neuropace's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Neuropace's interrelated accounts and indicators.
| -0.78 | -0.73 | 0.79 | -0.64 | -0.3 | ||
| -0.78 | 0.99 | -0.73 | 0.87 | 0.35 | ||
| -0.73 | 0.99 | -0.66 | 0.85 | 0.24 | ||
| 0.79 | -0.73 | -0.66 | -0.53 | -0.8 | ||
| -0.64 | 0.87 | 0.85 | -0.53 | 0.23 | ||
| -0.3 | 0.35 | 0.24 | -0.8 | 0.23 |
Click cells to compare fundamentals
Neuropace Revenue Historical Pattern
Today, most investors in Neuropace Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Neuropace's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Neuropace revenue as a starting point in their analysis.
Neuropace Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Neuropace Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Neuropace reported 65.42 M of revenue. This is 99.14% lower than that of the Health Care Equipment & Supplies sector and 97.44% lower than that of the Health Care industry. The revenue for all United States stocks is 99.31% higher than that of the company.
Neuropace Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neuropace's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neuropace could also be used in its relative valuation, which is a method of valuing Neuropace by comparing valuation metrics of similar companies.Neuropace is currently under evaluation in revenue category among its peers.
Neuropace ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Neuropace's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Neuropace's managers, analysts, and investors.Environmental | Governance | Social |
Neuropace Institutional Holders
Institutional Holdings refers to the ownership stake in Neuropace that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Neuropace's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Neuropace's value.| Shares | Fmr Inc | 2024-09-30 | 249.4 K | Northern Trust Corp | 2024-09-30 | 159.8 K | State Street Corp | 2024-06-30 | 142.6 K | Renaissance Technologies Corp | 2024-09-30 | 87 K | Charles Schwab Investment Management Inc | 2024-09-30 | 36.5 K | Bank Of New York Mellon Corp | 2024-06-30 | 34.1 K | Bridgeway Capital Management, Llc | 2024-09-30 | 33.2 K | Bank Of Montreal | 2024-06-30 | 32.2 K | Bmo Capital Markets Corp. | 2024-06-30 | 32.2 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 4.9 M | Orbimed Advisors, Llc | 2024-06-30 | 3.4 M |
Neuropace Fundamentals
| Return On Equity | -2.15 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.37) % | ||||
| Operating Margin | (0.20) % | ||||
| Current Valuation | 322.61 M | ||||
| Shares Outstanding | 29.85 M | ||||
| Shares Owned By Insiders | 4.10 % | ||||
| Shares Owned By Institutions | 82.89 % | ||||
| Number Of Shares Shorted | 290.4 K | ||||
| Price To Book | 31.15 X | ||||
| Price To Sales | 4.00 X | ||||
| Revenue | 65.42 M | ||||
| Gross Profit | 32.49 M | ||||
| EBITDA | (22.83 M) | ||||
| Net Income | (32.96 M) | ||||
| Cash And Equivalents | 92.41 M | ||||
| Cash Per Share | 3.72 X | ||||
| Total Debt | 72.39 M | ||||
| Debt To Equity | 1.08 % | ||||
| Current Ratio | 9.86 X | ||||
| Book Value Per Share | 0.33 X | ||||
| Cash Flow From Operations | (19.7 M) | ||||
| Short Ratio | 2.70 X | ||||
| Earnings Per Share | (0.98) X | ||||
| Target Price | 14.29 | ||||
| Number Of Employees | 184 | ||||
| Beta | 1.8 | ||||
| Market Capitalization | 305.94 M | ||||
| Total Asset | 107.65 M | ||||
| Retained Earnings | (503.81 M) | ||||
| Working Capital | 76.49 M | ||||
| Net Asset | 107.65 M |
About Neuropace Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neuropace's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neuropace using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neuropace based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neuropace is a strong investment it is important to analyze Neuropace's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuropace's future performance. For an informed investment choice regarding Neuropace Stock, refer to the following important reports:Check out Neuropace Piotroski F Score and Neuropace Altman Z Score analysis. For information on how to trade Neuropace Stock refer to our How to Trade Neuropace Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuropace. If investors know Neuropace will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuropace listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.98) | Revenue Per Share 2.697 | Quarterly Revenue Growth 0.282 | Return On Assets (0.15) | Return On Equity (2.15) |
The market value of Neuropace is measured differently than its book value, which is the value of Neuropace that is recorded on the company's balance sheet. Investors also form their own opinion of Neuropace's value that differs from its market value or its book value, called intrinsic value, which is Neuropace's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuropace's market value can be influenced by many factors that don't directly affect Neuropace's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuropace's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuropace is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuropace's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.